Nuvectis Pharma (NVCT) Preferred Stock Liabilities (2021)

Nuvectis Pharma has reported Preferred Stock Liabilities for 1 years, with the latest figure at $15.2 million in Q4 2021.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $15.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $15.2 million (changed N/A YoY) and the FY2021 annual result came in at $15.2 million, changed N/A from the prior year.
• Preferred Stock Liabilities was little changed at $15.2 million in Q4 2021 per NVCT's latest filing, from $15.2 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $15.2 million in Q3 2021 and troughed at $11.2 million in Q2 2021.